Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) · 2011
Spontaneous echocardiographic contrast in three dogs.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ralph Alan G, Saunders Ashley B, Hariu Crystal D, Nabity Mary
Аннотация
OBJECTIVE: To describe the clinical presentation and outcome in 3 dogs with spontaneous echocardiographic contrast (SEC).
CASE OR SERIES SUMMARY: SEC was identified in 3 dogs with concurrent hyperfibrinogenemia. The dogs were diagnosed with different underlying conditions including infective endocarditis of the mitral valve (Case 1), presumptive Evan's syndrome (Case 2), and presumptive sepsis (Case 3). Various therapies were used in each case directed at their underlying condition, in addition to thromboprophylaxis that were based upon a perceived risk of thromboembolic disease. The 3 dogs in this series survived to discharge and had good outcome during the follow-up period, which ranged from 3 weeks to 7 months.
NEW OR UNIQUE INFORMATION PROVIDED: SEC is considered a marker for thromboembolic disease in people and can occur in dogs in the absence of significant cardiomegaly. SEC in these 3 dogs may be related to the documented hyperfibrinogenemia. Further investigation is warranted to determine whether dogs with SEC are at an increased risk for thromboembolic complications.
CASE OR SERIES SUMMARY: SEC was identified in 3 dogs with concurrent hyperfibrinogenemia. The dogs were diagnosed with different underlying conditions including infective endocarditis of the mitral valve (Case 1), presumptive Evan's syndrome (Case 2), and presumptive sepsis (Case 3). Various therapies were used in each case directed at their underlying condition, in addition to thromboprophylaxis that were based upon a perceived risk of thromboembolic disease. The 3 dogs in this series survived to discharge and had good outcome during the follow-up period, which ranged from 3 weeks to 7 months.
NEW OR UNIQUE INFORMATION PROVIDED: SEC is considered a marker for thromboembolic disease in people and can occur in dogs in the absence of significant cardiomegaly. SEC in these 3 dogs may be related to the documented hyperfibrinogenemia. Further investigation is warranted to determine whether dogs with SEC are at an increased risk for thromboembolic complications.